Gender differences in antiretroviral drug-related adipose tissue alterations: Women are at higher risk than men and develop particular lipodystrophy patterns

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 1, 2003, Pages 58-61

  Galli, Massimo ^c   Veglia, Fabrizio ^a   Angarano, Gioacchino ^e   Santambrogio, Sara ^e   Meneghini, Elena ^b   Gritti, Francesco ^e   Cargnel, Antonietta ^c   Mazzotta, Francesco ^d   Lazzarin, Adriano ^b  

^a ISI FOUNDATION   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^e Ospedale Luigi Sacco ^*

Author keywords

Adipose tissue abnormalities; Antiretroviral treatment; Lipoatrophy

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADIPOSE TISSUE; ADIPOSE TISSUE ALTERATION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG USE; FEMALE; GENDER; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LEUKOCYTE COUNT; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; SEX DIFFERENCE; SUBCUTANEOUS FAT DISORDER; VIRUS LOAD;

ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; ITALY; LIPODYSTROPHY; LOGISTIC MODELS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SEX CHARACTERISTICS;

EID: 0041914142     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200309010-00008     Document Type: Article

References (15)

1. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-2505.
2. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.
3. Galli M, Cozzi-Lepri A, Ridolfo AL, et al., for the LipoICoNa study. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICONA study. Arch Intern Med. 2002;162:2621-2628.
4. Kotler DP, Lopes J, Engelson ES, et al. Interaction among sex, HIV infection and fat redistribution. AIDS Reader. 2000;10:589-594.
5. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-139.
6. Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 1999;84:1932-1937.
7. Falutz J, Muurahainen N, Workman C, et al. Gender is associated with increased body size but not fat depletion in patients with HIV-associated adipose redistribution syndrome (HARS). Paper presented at: XIII International AIDS Conference; July 9-14, 2002; Durban, South Africa. Abstract WePeB 4273.
8. Galli M, Polo R, Saint-Marc T, et al. for the ART-associated Lipodystrophy European Collaborative Study (ALECS) group. Guidelines to describe morphologic and metabolic alterations (MMA) under ART: the Marrakech classification. Nutr Metab Disorders HIV Infect. 2002;1:25-29.
9. Saint Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
10. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:21-31.
11. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis. 2000;31:1482-1487.
12. Saves M, Raffi F, Capeau J, et al. The Antiproteases Cohort (APROCO) Study Group. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34:1396-1405.
13. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-471.
14. Galli M, Ridolfo AL, Adorni F, et al. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1 infected women treated with antiretroviral therapy. Antivir Ther. 2003. In press.
15. Hadigan C, Corcoran C, Piecuch S, et al. Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome. J Clin Endocrinol Metab. 2000;85:3544-3550.